Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC? – Video




Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC?
Dr. Joel Neal from Stanford University Medical School talks about erlotinib, filmed at IASLC in February 2014. Oncology.TV would like to acknowledge CancerGrace.org and the Lungevity Foundation...

By: Oncology.TV

Visit link:
Will Erlotinib Prevent Disease Recurrence in Patients with Early Stage EGFR Positive NSCLC? - Video

Related Posts

Comments are closed.